Get the Stockscreener App
6.76
1.05%
0.07
After Hours:
6.75
-0.010
-0.15%
Anbio Biotechnology stock is traded at $6.76, with a volume of 433.90K.
It is up +1.05% in the last 24 hours and up +0.00% over the past month.
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. IVD products are designed to detect a wide range of biomarkers associated with critical medical domains. Its research and development activities for all IVD products: Biomarker Discovery and Validation, Assay Development, Validation - Clinical and Analytical and Platform Transfer. Its product AF-1200 Fluorescence Immunoassay Analyzer, AF-100 Fluorescence Immunoassay Analyzer, AF-100S Fluorescence Immunoassay Analyzer, AF-100C Fluorescence Immunoassay Analyzer.
See More
Previous Close:
$6.69
Open:
$6.95
24h Volume:
433.90K
Relative Volume:
23.23
Market Cap:
$337.96M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+8.68%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$6.75
$7.6999
1-Week Range:
$6.04
$7.6999
52-Week Range:
$5.60
$7.6999
Anbio Biotechnology Stock (NNNN) Company Profile
Name
Anbio Biotechnology
Sector
Industry
Phone
-
Address
-
Compare NNNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNNN
Anbio Biotechnology
|
6.76 | 337.96M | 0 | 0 | 0 | 0.00 |
|
ISRG
Intuitive Surgical Inc
|
566.98 | 205.74B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
228.45 | 65.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
94.14 | 46.26B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
233.10 | 34.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
91.65 | 18.19B | 3.90B | 392.30M | 288.10M | 1.95 |
Anbio Biotechnology Stock (NNNN) Latest News
Kestra Medical ups IPO target to $150M - BioWorld Online
Unlocking Anbio's IPO: A Pivotal Shift in Global Diagnostics! - Mi Valle
U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings - Seeking Alpha
IPO NewsUS IPO Weekly Recap: IPO calendar slows down with small listings - Renaissance Capital
Undiscovered Gems In The US Featuring Anbio Biotechnology And 2 Other Small Caps - Yahoo Finance
Anbio Biotechnology prices $8M IPO at $5 per share - MSN
Anbio Biotechnology’s IPO opens up 5% - Investing.com
Anbio Biotechnology’s IPO Set to Revolutionize Global Diagnostics - Mi Valle
NNNNAnbio Biotechnology Latest Stock News & Market Updates - StockTitan
Anbio Biotechnology to Showcase Cutting-Edge Diagnostic Solutions at 2025 Medlab Middle East - PR Newswire
Anbio Biotechnology Unveils Dry Chemiluminescence Immunoassay (CLIA) Solution: Redefining Diagnostic Precision and Efficiency - PR Newswire
Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch - Seeking Alpha
Anbio Biotechnology Unveils Comprehensive In-Vitro-Diagnostics Solutions at ADLM 2024 - PR Newswire
Anbio Biotechnology to Showcase at ADLM 2024 with Evolved In Vitro Diagnostic Solutions - PR Newswire
Anbio advances POC testing with new FIA analyzer - SelectScience
Anbio Biotechnology to Showcase ABO & Rhd Blood Grouping Kit at Medlab Middle East 2024 - PR Newswire
Anbio Biotechnology to Present at Medlab Middle East on February 5th, 2024. - PR Newswire
Anbio Biotechnology made a successful first presence at AACC Middle East 2023 - BioSpace
Handheld Analyzer Uses LAMP Diagnostic Technique for Rapid, Point-of-Care Testing - HospiMedica
Anbio Biotechnology Highlights the Future of Diagnostic Solutions at AACC 2023 - PR Newswire
Anbio launches fluorescent immunoassay analyzer for rapid, point-of-care testing - BioWorld Online
Introducing the Anbio LAMP Solution: A Small, Yet Powerful Handheld Analyzer for Rapid, Point-of-Care Testing - PR Newswire
Anbio introduces fluorescent Immunoassay solution for patient care - Medical Device Network
Introducing the Anbio AF-100S: A Small, Yet Powerful Handheld Analyzer for Rapid, Point-of-Care Testing - PR Newswire
Introducing the Anbio ADL i1910: An Elegant CLIA Analyzer for Comprehensive Clinical Testing - PR Newswire
Anbio Biotechnology to Participate in the 2023 AACC Meeting - PR Newswire
AnHeart Therapeutics Raises $61 Million in Oversubscribed Series B Financing to Advance Precision Oncology Pipeline - Business Wire
Anbio Biotechnology Stock (NNNN) Financials Data
There is no financial data for Anbio Biotechnology (NNNN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
4.97%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):